NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 1000120-98-8
Drug Levels and Effects
Summary of Use during Lactation
No relevant published information exists with the use of mipomersen during breastfeeding. Because of a concern with disruption of infant lipid metabolism, mipomersen should not be used during breastfeeding.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Mipomersen
CAS Registry Number
1000120-98-8
Drug Class
- Breast Feeding
- Anticholesteremic Agents
- Antilipemic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.[Clin Pharmacokinet. 2009]Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.Yu RZ, Geary RS, Flaim JD, Riley GC, Tribble DL, vanVliet AA, Wedel MK. Clin Pharmacokinet. 2009; 48(1):39-50.
- Review Fluvastatin[Drugs and Lactation Database (...]Review Fluvastatin. Drugs and Lactation Database (LactMed). 2006
- Review Lomitapide[Drugs and Lactation Database (...]Review Lomitapide. Drugs and Lactation Database (LactMed). 2006
- Review Fenofibrate[Drugs and Lactation Database (...]Review Fenofibrate. Drugs and Lactation Database (LactMed). 2006
- Review Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.[Vasc Health Risk Manag. 2012]Review Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.Bell DA, Hooper AJ, Watts GF, Burnett JR. Vasc Health Risk Manag. 2012; 8:651-9. Epub 2012 Nov 28.
- Mipomersen - Drugs and Lactation Database (LactMed)Mipomersen - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...